Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid

Journal of Bone and Mineral Research

Volumn 21, Issue 5, 2006, Pages 765-771

  Udell, Jacob A ^a,b   Fischer, Michael A ^a   Brookhart, M Alan ^a   Solomon, Daniel H ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bisphosphonate; Estrogen; Medicaid; Osteoporosis; Women's health

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; PAMIDRONIC ACID; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; ELDERLY CARE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; OSTEOPOROSIS; POSTMENOPAUSE; PRESCRIPTION; REIMBURSEMENT; TIME SERIES ANALYSIS;

CALCITONIN; CALCIUM; COST OF ILLNESS; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDICAID; OSTEOPOROSIS; RALOXIFENE; UNITED STATES; WOMEN'S HEALTH;

EID: 33646265558     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060119     Document Type: Article

References (42)

1. National Osteoporosis Foundation 2003 America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. National Osteoporosis Foundation, Washington, DC. USA.
2. Tosteson AN, Hammond CS 2002 Quality-of-life assessment in osteoporosis: Health-status and preference-based measures. Pharmacoeconomics 20:289-303.
3. Cheung AM, Feig DS, Kapral M, Diaz-Granados N, Dodin S 2004 Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 170:1665-1667.
4. Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J 2003 Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 115:398-400.
5. Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH 2003 Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052-2057.
6. Nelson HD, Rizzo J, Harris E, Cauley J, Ensrud K, Bauer DC, Orwoll E; for the Study of Osteoporotic Fractures Research Group. 2002 Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 162:2278-2284.
7. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Johnell O, Johnston CC Jr, Lau EM, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Miller PD, Mithal A, Moril H, Papapoulos S, Woolf A, Yu W, Khaltaer N 1999 Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259-264.
8. NIH Consensus Development Panel on Osteoporosis Prevention 2001 Diagnosis, and Treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
9. Lee E, Zuckerman IH, Weiss SR 2002 Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women. Arch Intern Med 162:2362-2366.
10. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ 1999 Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130:545-553.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; for the Writing Group for the Women's Health Initiative Investigators. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
12. Austin PC, Mamdani MM, Tu K, Jaakkimainen L 2003 Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Heath Initiative study. JAMA 289:3241-3242.
13. Haas JS, Kaplan CP, Gerstenberger EP, Kërlikowske K 2004 Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184-188.
14. Lawton B, Rose S, McLeod D, Dowell A 2003 Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: Cross sectional survey of users. BMJ 327:845-846.
15. Hersh AL, Stefanick ML, Stafford RS 2004 National use of postmenopausal hormone replacement therapy: Annual trends and response to recent evidence. JAMA 291:47-53.
16. MacLennan AH, Taylor AW, Wilson DH 2004 Hormone therapy use after the Women's Health Initiative. Climacteric 7:138-142.
17. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, Sarra S 2004 Patients' and clinicians' attitudes after the Women's Health Initiative Study. Menopause 11:57-61.
18. Leung KY, Ling M, Tang GWK 2005 Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial. Maturitas 52:277-285.
19. Keinan-Boker L, Dictiar R, Garty N, Green MS 2005 Prevalence and correlates of hormonal therapy among Israeli women in the post-WHI era. Maturitas 52:364-373.
20. Wathen CN, Feig DS, Feightner JW, Abramson BL, Cheung AM 2004 Hormone replacement therapy for the primary prevention of chronic diseases: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 170:1535-1539.
21. US Preventive Services Task Force 2002 Hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale. Available at http:// www.ahrq.gov/clinic/3rduspstf/hrt/hrtrr.htm. Accessed December 1, 2004.
22. Drug Topics Red Book 2004 Thomson PDR, Montvale, NJ, USA.
23. Perkins J 2004 "Medicaid," in Poverty Law Manual for the New Lawyer. National Center on Poverty Law, Chicago, IL, USA.
24. Anonymous 2004 Medicaid's role for women. Available at http://www.kff.org/womenshealth/upload/Medicaid-s-Role-for-Women.pdf. Accessed December 1, 2004.
25. National Family Planning & Reproductive Health Association 2004 Medicaid: A vital source of health care for low income women and a critical source of support-for family planning services. Available at http://www.nfprha.org/pac/factsheets/ medicaid.asp. Accessed December 1, 2005.
26. Bruen B, Ghosh A 2004 Medicaid prescription drug spending and use. Kaiser Commission on Medicaid and the uninsured. Available at http://www.kff.org/ medicaid/upload/Medicaid-Prescription-Drug-Spending-and-Use.pdf. Accessed December 1, 2004.
27. Centers for Medicare and Medicaid Services 2004 State Drug Utilization Data. Centers for Medicare and Medicaid Services, Baltimore, MD, USA.
28. Centers for Medicare and Medicaid Services 2004 Medicaid Statistical Information System Statistical Reports for Federal Fiscal Years 1999-2004. Centers for Medicare and Medicaid Services, Baltimore, MD, USA.
29. Centers for Medicare and Medicaid Services 2004 Medicaid enrollment and beneficiaries, selected fiscal years. Available at http://www.cms.hhs.gov/ researchers/pubs/datacompendium/ 2003/03pg34.pdf. Accessed December 1, 2004.
30. de Klerk E 2001 Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 62:S43-S47.
31. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ III 2002 Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330.
32. Kirk D, Fish DA 2004 Medical management of osteoporosis. Am J Manag Care 10:445-455.
33. Johnell O, Jonsson B, Jonsson L, Black D 2003 Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314.
34. Mullins CD, Ohsfeldt RL 2003 Modeling the annual costs of postmenopausal prevention therapy: Raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 9:150-158.
35. Curtiss FR 2003 ERT, HRT, raloxifene, calcitonin, or bisphosphonates for osteoporosis. J Manag Care Pharm 9:178-180.
36. Curtiss FR 2004 Reducing the risk of fractures-the options narrow for cost-effective therapeutic alternatives. J Manag Care Pharm 10:168-179.
37. Pear R 2005 New Medicare Rules on Drugs Balance Access against Costs. New York Times. A5, January 22, 2005.
38. Stafford RS, Drieling RL, Hersh AL 2004 National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 164:1525-1530.
39. Federal Register 1998 63 FR 34320-34328. Medicare program: Medicare coverage of and payment for bone mass measurements. Available at http://frwebgate.access.gpo.gov/cgi-bin/ getdoc.cgi?IPaddress = &dbname = 1998_register&docid = 98-16783-filed. Accessed December 1, 2005.
40. The Henry J. Kaiser Family Foundation State Health Facts Web Site 2004 50 state comparisons: State mandated benefits: Osteoporosis screening. Available at http://statehealthfacts. org/cgi-bin/healthfacts.cgi?action = compare&category = Women%27s+Health&subcategory = Mandated+Benefits+ for+Women&topic = Osteoporosis+Screening. Accessed December 1, 2005.
41. Stafford RS, Saglam D, Causino M, Blumenthal D 1998 The declining impact of race and insurance status on hormone replacement therapy. Menopause 5:140-144.
42. Friedman-Koss D, Crespo CJ, Bellantoni MF, Anderson RE 2002 The relationship of race/ethnicity and social class to hormone replacement therapy: Results from the Third National Health and Nutrition Examination Survey 1988-1994. Menopause 9:264-272.